BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36639281)

  • 21. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.
    Anderson H; Hopwood P; Stephens RJ; Thatcher N; Cottier B; Nicholson M; Milroy R; Maughan TS; Falk SJ; Bond MG; Burt PA; Connolly CK; McIllmurray MB; Carmichael J
    Br J Cancer; 2000 Aug; 83(4):447-53. PubMed ID: 10945489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy.
    Lee H; Jin GY; Han YM; Chung GH; Lee YC; Kwon KS; Lynch D
    Cardiovasc Intervent Radiol; 2012 Apr; 35(2):343-50. PubMed ID: 21626257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance.
    Kuo CH; Lin SM; Lee KY; Chung FT; Hsieh MH; Fang YF; Yu CT; Kuo HP
    Clin Lung Cancer; 2010 Jan; 11(1):51-6. PubMed ID: 20085868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advanced non-small cell lung cancer in the elderly: the impact of age and comorbidities on treatment modalities and patient prognosis.
    Hsu CL; Chen JH; Chen KY; Shih JY; Yang JC; Yu CJ; Yang PC
    J Geriatr Oncol; 2015 Jan; 6(1):38-45. PubMed ID: 25245172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lung cancer in New Zealand: patterns of secondary care and implications for survival.
    Stevens W; Stevens G; Kolbe J; Cox B
    J Thorac Oncol; 2007 Jun; 2(6):481-93. PubMed ID: 17545842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
    Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
    Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multi-institutional survey of thymic carcinoma patients in Hokushin region.
    Uramoto H; Takiguchi T; Koizumi T; Tanimoto A; Hayashi R; Nakazawa Y; Ito KI; Nakada M; Hirono Y; Nishino Y; Yano S
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):419-424. PubMed ID: 33963906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variation in treatment and outcome in patients with non-small cell lung cancer by region, hospital type and volume in the Netherlands.
    Wouters MW; Siesling S; Jansen-Landheer ML; Elferink MA; Belderbos J; Coebergh JW; Schramel FM
    Eur J Surg Oncol; 2010 Sep; 36 Suppl 1():S83-92. PubMed ID: 20598845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of a 'Watch and Wait' Approach for Chemotherapy in Patients with Newly Diagnosed Advanced Non-small Cell Lung Cancer from a Diverse Community Population.
    Noonan K; Tong KM; Laskin J; Zheng YY; Melosky B; Sun S; Murray N; Ho C
    Clin Oncol (R Coll Radiol); 2015 Sep; 27(9):505-13. PubMed ID: 26095646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the efficacy and safety of chemotherapy for patients with wet stage IIIB/IV non-small-cell lung cancer aged 80 years old or more.
    Tamiya A; Naito T; Ono A; Ayabe E; Tsuya A; Nakamura Y; Kaira K; Murakami H; Takahashi T; Endo M; Yamamoto N
    Lung Cancer; 2011 Feb; 71(2):173-7. PubMed ID: 20570388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy.
    Thongprasert S; Sanguanmitra P; Juthapan W; Clinch J
    Lung Cancer; 1999 Apr; 24(1):17-24. PubMed ID: 10403690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Active Treatment Improves Overall Survival in Extremely Older Non-Small Cell Lung Cancer Patients: A Multicenter Retrospective Cohort Study.
    Lee SY; Hong YK; Ji W; Lee JC; Choi CM; ;
    Cancer Res Treat; 2021 Jan; 53(1):104-111. PubMed ID: 33017882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.
    Minegishi Y; Yamaguchi O; Sugawara S; Kuyama S; Watanabe S; Usui K; Mori M; Hataji O; Nukiwa T; Morita S; Kobayashi K; Gemma A
    BMC Cancer; 2021 Mar; 21(1):208. PubMed ID: 33648453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy.
    Goldman JW; Shi P; Reck M; Paz-Ares L; Koustenis A; Hurt KC
    Clin Lung Cancer; 2016 Jan; 17(1):80-4. PubMed ID: 26432508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.
    Brodowicz T; Krzakowski M; Zwitter M; Tzekova V; Ramlau R; Ghilezan N; Ciuleanu T; Cucevic B; Gyurkovits K; Ulsperger E; Jassem J; Grgic M; Saip P; Szilasi M; Wiltschke C; Wagnerova M; Oskina N; Soldatenkova V; Zielinski C; Wenczl M;
    Lung Cancer; 2006 May; 52(2):155-63. PubMed ID: 16569462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry.
    Kocher F; Hilbe W; Seeber A; Pircher A; Schmid T; Greil R; Auberger J; Nevinny-Stickel M; Sterlacci W; Tzankov A; Jamnig H; Kohler K; Zabernigg A; Frötscher J; Oberaigner W; Fiegl M
    Lung Cancer; 2015 Feb; 87(2):193-200. PubMed ID: 25564398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy versus best supportive care for extensive small cell lung cancer.
    Pelayo Alvarez M; Westeel V; Cortés-Jofré M; Bonfill Cosp X
    Cochrane Database Syst Rev; 2013 Nov; (11):CD001990. PubMed ID: 24282143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of age on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer.
    Zhai X; Yang L; Chen S; Zheng Q; Wang Z
    Cancer Med; 2016 Sep; 5(9):2286-93. PubMed ID: 27367482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world outcomes of chemotherapy for lung cancer patients undergoing hemodialysis: A multicenter retrospective cohort study (NEJ-042).
    Minegishi Y; Akagami T; Arai M; Saito R; Arai D; Murase K; Miura K; Watanabe S; Sakashita H; Miyabayashi T; Honda R; Jingu D; Hotta T; Isobe K; Nakazawa K; Ito K; Takamura K; Inomata M; Harada T; Sakakibara R; Nakagawa T; Shibuya H; Takenaka K; Kobayashi K; Seike M
    Lung Cancer; 2022 Oct; 172():1-8. PubMed ID: 35952438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.